2 Beaten-Down Stocks That Could Rocket 142% to 222% Higher, According to Wall Street AnalystsThe Motley Fool • 08/29/25
Does Lilly's New Obesity Pill Data Put It Back in the Weight Game?Zacks Investment Research • 08/27/25
LLY vs. PFE: Which Pharma Giant Is the Better Pick for Investors?Zacks Investment Research • 08/27/25
Eli Lilly's Obesity Pill Breakthrough Shakes Up $150 Billion Weight-Loss Race24/7 Wall Street • 08/27/25
The bear case on Eli Lilly has played out, says only firm to have called it a sellMarket Watch • 08/27/25
Lilly's Verzenio® (abemaciclib) increases overall survival in HR+, HER2-, high-risk early breast cancer with two years of therapyPRNewsWire • 08/27/25
S&P 500 Gains and Losses Today: Eli Lilly Stock Soars as Weight-Loss Pill Shows Promise; Beverage Makers Face PressureInvestopedia • 08/26/25
Healthy Returns: Eli Lilly's chief scientific officer breaks down the latest obesity pill dataCNBC • 08/26/25
Eli Lilly advances weight loss pill towards regulatory submissions after successful trialProactive Investors • 08/26/25
Lilly obesity-pill trial results find a warmer reception on Wall Street this time aroundMarket Watch • 08/26/25